PD-1 blockade can “remove the brakes” placed on host immune responses by PD pathway signaling at tumor sites, however the ultimate antitumor effect is constrained by the host’s ability to generate adaptive immune responses against tumor-associated antigens, an ability that is often significantly impaired in GBM. This evidence concerns the gene PDCD1 and glioblastoma.